Stokes Capital Advisors LLC Lowers Position in Stryker Corporation $SYK

Stokes Capital Advisors LLC trimmed its holdings in shares of Stryker Corporation (NYSE:SYK) by 13.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,671 shares of the medical technology company’s stock after selling 3,722 shares during the period. Stryker comprises about 1.7% of Stokes Capital Advisors LLC’s portfolio, making the stock its 28th largest position. Stokes Capital Advisors LLC’s holdings in Stryker were worth $7,778,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Brighton Jones LLC increased its holdings in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. purchased a new stake in Stryker during the second quarter worth $205,000. Marshall Wace LLP boosted its position in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC purchased a new position in shares of Stryker in the 2nd quarter valued at $219,000. Finally, HUB Investment Partners LLC purchased a new stake in shares of Stryker during the 2nd quarter worth $253,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK opened at $316.41 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a market cap of $121.30 billion, a PE ratio of 36.62, a P/E/G ratio of 2.01 and a beta of 0.78. The business has a 50-day simple moving average of $311.29 and a two-hundred day simple moving average of $339.98. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.

Analyst Ratings Changes

Several equities analysts have issued reports on SYK shares. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. UBS Group lowered their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. William Blair reaffirmed an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. lowered their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $395.33.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.